International Journal of Nephrology / 2018 / Article / Tab 3

Research Article

Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders

Table 3

Base case results (3% discount on costs and outcomes).

TreatmentLifetime cost per patient (RM)Effect (LY)ICER (Cost per LY gained)Effect (QALY)ICER (Cost per QALY gained)

CaCO377,1394.25-3.54-
Sevelamer159,9016.37-5.27-
Incremental82,7632.1239,0501.7447,679